GABA/benzodiazepine receptor Inhibitors
1 drugsAbout GABA/benzodiazepine receptor
The GABA/benzodiazepine receptor is a crucial component of neuronal signaling in the central nervous system (CNS), mediating the effects of GABA to facilitate inhibitory neurotransmission in the brain.
Modulation of this receptor offers therapeutic potential for various CNS conditions; however, there is currently no genetic evidence linking this target to specific diseases.
ZONEGRAN (ADVANZ PHARMA) is the sole FDA-approved drug targeting this receptor, formulated as a small molecule for CNS indications since 2000.
Top GABA/benzodiazepine receptor Drugs
ADVANZ PHARMA is the only company with an approved drug targeting the GABA/benzodiazepine receptor.
Low competition may indicate high entry barriers or limited market potential; conduct thorough market analysis.
GABA/benzodiazepine receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets GABA/benzodiazepine receptor, using small molecule modality.
Explore novel modalities like antibodies or gene therapies to differentiate from existing small molecule approaches.
GABA/benzodiazepine receptor Clinical Trials 37 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on GABA/benzodiazepine receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 3 | 1 | 0 | 75% |
| Phase 2 | 11 | 3 | 7 | 1 | 30% |
| Phase 3 | 13 | 10 | 3 | 0 | 77% |
| Phase 4 | 9 | 5 | 1 | 2 | 83% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
GABA/benzodiazepine receptor Drug Approval Timeline (2000 - 2000)
The first and only drug, ZONEGRAN, was approved in 2000, marking a long period without new approvals.
The lack of recent approvals suggests potential saturation or challenges in developing new GABA/benzodiazepine receptor modulators.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 24 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on GABA/benzodiazepine receptor. A trial counts if an approved drug acting on GABA/benzodiazepine receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.